JPH02152469A - Drug capsule - Google Patents
Drug capsuleInfo
- Publication number
- JPH02152469A JPH02152469A JP63306624A JP30662488A JPH02152469A JP H02152469 A JPH02152469 A JP H02152469A JP 63306624 A JP63306624 A JP 63306624A JP 30662488 A JP30662488 A JP 30662488A JP H02152469 A JPH02152469 A JP H02152469A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- capsule
- outside
- discharge
- embedded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 92
- 229940079593 drug Drugs 0.000 title claims abstract description 90
- 239000002775 capsule Substances 0.000 title claims abstract description 41
- 230000035939 shock Effects 0.000 abstract description 8
- 210000000988 bone and bone Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 239000012528 membrane Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 238000002513 implantation Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000001066 destructive effect Effects 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 239000010409 thin film Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野１
本発明は、薬剤の放出開始１１ｉ明及びその放出速＋Ｕ
を生体の外部から制御“Ｃ−きるＪ−うにした薬剤力１
ビルに関する。Detailed Description of the Invention [Industrial Field 1] The present invention is directed to
control from outside the living body
Regarding buildings.
［従来の技術］
人間或いは動物の病気を治療するための薬剤を投与りる
方法として、薬剤を外斜的に牛体内に理め込んで使用す
る埋め込み薬剤が知られている。[Prior Art] As a method for administering drugs to treat diseases in humans or animals, implantable drugs are known in which the drugs are externally inserted into the cow's body.
この埋め込み薬剤は、経１」投与桑や注射等と比較して
、大きな治療効果を期待できるｂのである。This implantable drug can be expected to have greater therapeutic effects than oral administration or injections.
［発明が解決しようとする課題］
しかしながら、この埋め込み薬剤は、時として、この埋
め込み式薬剤を埋め込むための処置や、この理め込みと
合わせて行なわれる処置にＪ、って生体に与える侵襲と
、元来多くの薬剤が有している副作用との相乗効果によ
り、かえって冶癒速度がｄくなったり、処置部位の組織
の壊死等の障害を引さ起こＪこともあった。[Problems to be Solved by the Invention] However, this implantable drug is sometimes invasive to the living body during the procedure for implanting the implantable drug and the procedure performed in conjunction with the implantation. However, due to the synergistic effect with the side effects that many drugs originally have, the healing rate may be slowed down or damage such as necrosis of the tissue at the treated site may be caused.
［発明の目的１
本発明は、上記事情に鑑み−Ｃなされたものであり、体
外から薬剤の放出時期やその速度を制御可能なｐＩ！め
込み薬剤用の薬剤カブビルを提供することを目的と１６
゜
［課題を解決するための手段］
本発明の薬剤カプセルは、薬剤を収納づるための薬剤カ
プセル本体と、前記薬剤カプセル本体に収納された薬剤
を放出−するために該カプセル本体に設けた薬剤放出部
位と、前記薬剤放出部位を閉塞し外部からの作用により
該薬剤放出部位を開放可能な閉塞部材とを具備するもの
である。[Objective of the Invention 1] The present invention has been made in view of the above-mentioned circumstances, and it is possible to control the release timing and rate of a drug from outside the body. 16 with the aim of providing the drug Kabuvir for inlay drugs.
[Means for Solving the Problems] The drug capsule of the present invention includes a drug capsule body for storing a drug, and a drug provided in the capsule body for releasing the drug stored in the drug capsule body. The device includes a release site and a closing member that closes the drug release site and can open the drug release site by an external action.
［作用］
即ち、本発明の薬剤カプセルにおいては、薬剤放出部位
を閉塞する閉塞部材が、外部からの作用によって破壊さ
れて、薬剤放出部位から薬剤が放出される。[Operation] That is, in the drug capsule of the present invention, the closing member that closes the drug release site is destroyed by an external action, and the drug is released from the drug release site.
［実施例］
以下、添附図面を参照しながら本発明の各実施例につい
て述べる。[Example] Hereinafter, each example of the present invention will be described with reference to the accompanying drawings.
第１図は本発明の第１実施例の薬剤カプセルの構成を示
す断面図である。FIG. 1 is a sectional view showing the structure of a drug capsule according to a first embodiment of the present invention.
この図に示すように、本実施例の薬剤カプセルは、生体
に対する適合性を有する材料により形成されたカプセル
本体１と、薬剤を放出するための放出部位としての放出
孔３と、この放出孔３の上に設けられており、生体への
適合性を有する索材により形成されていて、前記カプセ
ル本体１よりも小さなエネルギにより破壊可能な閉塞部
祠としての薄１］！ｉ１４とにより構成されており、前
記カプセル本体１内には、薬剤２が収容されるようにな
っている。As shown in this figure, the drug capsule of this embodiment includes a capsule body 1 formed of a material that is compatible with living organisms, a release hole 3 as a release site for releasing the drug, and a release hole 3. Thin 1], which serves as an obstruction shrine, is provided on the capsule body 1 and is formed of a cable material that is compatible with the living body, and can be destroyed by an energy smaller than that of the capsule body 1! i14, and the drug 2 is accommodated in the capsule body 1.
尚、前記カプセル本体１を構成する材料としては、チタ
ン、チタン合金、ステンレス、コバルト９０１８合金等
の金属材料や、アルミナ、ハイドロキシアバタイ１〜、
β−ＴＣＰ （β−リ、ン酸３カルシウム）等のセラミ
ックス材料や、シリコン樹脂、ポリエーテルナルホン、
ポリテトラフルオロエチレン等の高分子材料等が挙げら
れる。The capsule body 1 may be made of metal materials such as titanium, titanium alloy, stainless steel, or cobalt 9018 alloy, alumina, hydroxyl abutite 1, etc.
Ceramic materials such as β-TCP (β-tricalcium phosphate), silicone resin, polyether nalphone,
Examples include polymeric materials such as polytetrafluoroethylene.
又、前記薬剤２とし一〇は、各種ホルモン、抗生物質、
抗ガン剤等を、治療目的や治療対象の部位に応じて任意
に使用できる。In addition, the drugs 2 and 10 are various hormones, antibiotics,
Anticancer drugs and the like can be used as desired depending on the therapeutic purpose and the area to be treated.
次に、この薬剤カプレルを埋め込み薬剤として実際に使
用したときの動作についで、第２図を参照しながら述べ
る。Next, the operation when this drug caprel is actually used as an implanted drug will be described with reference to FIG.
まず、外科的な処置により、薬剤カプセルを体内に留置
づる。そして、図示しない発振器等により、この埋め込
み薬剤に向けて超音波、低周波、ｆｔＩ撃波等を加える
。これにより、第２図に示づように、薄膜４が破壊して
、放出孔３から薬剤２が放出される。First, a drug capsule is placed in the body through a surgical procedure. Then, using an oscillator (not shown) or the like, ultrasonic waves, low frequency waves, ftI shock waves, etc. are applied to the implanted drug. As a result, as shown in FIG. 2, the thin film 4 is destroyed and the drug 2 is released from the release hole 3.
このように、本実施例によれば、体外からの超音波或い
は衝撃波により薄膜が破壊されて薬剤が放出されるので
、この体外からの超音波或いｔまトドｉ撃波を制御する
ことにより、この薄膜が破壊される時期、即ち薬剤が放
出される時期を制御づ′ることができる。このため、例
えば外科的な侵襲が癒えた時点で薬剤の放出を開始ざＵ
ることにより、０１作用を低減ざけることができる。As described above, according to this embodiment, the thin film is destroyed by ultrasonic waves or shock waves from outside the body and the drug is released, so by controlling the ultrasonic waves or shock waves from outside the body, , it is possible to control the timing at which this thin film is destroyed, ie, the timing at which the drug is released. For this reason, for example, the release of the drug may begin once the surgical insult has healed.
By doing so, the 01 effect can be reduced.
第３図（ま、本発明の第２実施例の薬剤放出部材の構成
を示す断面図である。FIG. 3 is a sectional view showing the structure of a drug release member according to a second embodiment of the present invention.
この第２実施例は、上記第１実施例ではカプセル本体１
よりも弱いエネルギにより破壊可能な材料により形成さ
れていた’；ＦＪ 躾４を、熱によって溶解、分解又は
変成を起こず材質により形成したものである。This second embodiment is different from the capsule body 1 in the first embodiment.
It is made of a material that does not melt, decompose, or metamorphose due to heat.
尚、前記材質としては、コラーゲン、ボリレ乳酸、ポリ
ごニルアルコールハイドロゲル等が挙げられる。In addition, examples of the material include collagen, boryle lactic acid, polygonyl alcohol hydrogel, and the like.
この第２実施例においては、体外からＲＦ波、マイクロ
波、超音波等を照ｑ・１シて熱を加えることにより、薄
膜４が溶解、分解又は変成を起こし、放出孔３から薬剤
２の放出が開始される。In this second embodiment, the thin film 4 is dissolved, decomposed, or denatured by applying heat by applying RF waves, microwaves, ultrasonic waves, etc. from outside the body, and the drug 2 is released from the release hole 3. Release begins.
この第２実施例のその伯の構成、作用及び効果は、上記
第１実施例と同様である。The configuration, operation, and effects of this second embodiment are the same as those of the first embodiment.
第４図＜ａ）は、本発明の第３実施例の薬剤カプセルの
構成を示す断面図である。FIG. 4<a) is a sectional view showing the structure of a drug capsule according to a third embodiment of the present invention.
この図に示すように、本実施例の薬剤カプセルは、薬剤
１１を収納していて生体への適合性を何りるセラミツ９
４４石又は高分子材料により構成された薬剤カプセル１
２の外部表面全体を、生体への適合性を有しでいて且つ
少なくとｂこの薬剤カプセル１２よりも弱いエネルギで
破壊可能な薄膜１３で覆ったしのぐある。As shown in this figure, the drug capsule of this example contains a ceramic 9 that houses the drug 11 and improves its compatibility with living organisms.
Pharmaceutical capsule 1 composed of 44 stones or polymeric material
The entire external surface of the drug capsule 2 is covered with a thin film 13 which is biocompatible and breakable with at least b lower energy than the drug capsule 12.
尚、前記薬剤カプセル１２は、透過性をＭ するマトリ
ックス中に薬剤１１を分散したものであり、この薬剤１
１は、マトリックス中を透過して放出されるようになっ
ている。The drug capsule 12 has the drug 11 dispersed in a matrix having a permeability of M.
1 is adapted to permeate through the matrix and be released.
尚、この薄膜１３の月オ］としては、ゼラミックス等が
挙げられる。Incidentally, examples of the material of the thin film 13 include Xeramix and the like.
この薬剤カブはル１２を実際に使用する際には、まず、
この理め込み薬剤１２を生体内に狸め込んで留置する。When actually using this drug Kabu Le 12, first,
This implanted drug 12 is implanted and left in the living body.
そして、体外からこの薬剤カプセル１２に向けて超８波
、低周波、衝撃波等を加える。Then, ultra-8 waves, low frequency waves, shock waves, etc. are applied to the drug capsule 12 from outside the body.
これにより、第４図（ｂ）に示Ｊように薄膜１３が破壊
、刺部されて、薬剤カプセル１２から薬剤１１の放出が
開始される。As a result, the thin film 13 is broken and punctured as shown in FIG. 4(b), and the release of the drug 11 from the drug capsule 12 is started.
この第３実施例のその他の部分のＩＭ成、作用及び効果
は、上記第１実施例と同様である。The IM structure, operation, and effects of other parts of this third embodiment are the same as those of the first embodiment.
尚、この第３実施例の薬剤カプセルを、第５図に示すよ
うな構成として、薬剤カプセル１５内にコラーゲンから
なる薬剤１４中に［３Ｍ ＋−）（母誘導タンパク）を
混入して、薄膜でコーディングすることもできる。The drug capsule of this third embodiment has a structure as shown in FIG. You can also code it with .
この埋め込み薬剤は、骨切除後の人工骨充ｋｉｔ ｌｌ
：’ｊや、人口関節の移植時等に、人工骨と合わせ−（
ｊ！Ｉ！め込ようにするものである。This implantable drug is used in the artificial bone filling kit ll after bone resection.
：'j or when transplanting an artificial joint, etc., in conjunction with an artificial bone.
j! I! It is something that you can immerse yourself in.
そして、埋め込んだ後に、体外からの超音波、衝撃波等
により薄膜を破壊することにより、薬剤１４を放出させ
て、［）の形成及び成長を促すことができる。After implantation, the thin film is destroyed by ultrasonic waves, shock waves, etc. from outside the body, thereby releasing the drug 14 and promoting the formation and growth of [).
第６図は、本発明の第４実施例を示すものである。FIG. 6 shows a fourth embodiment of the present invention.
この第４実施例は、複数の薬剤を使用する系に薬剤放出
部材を使用したちのである。２種類以上の薬剤を混合し
て使用することにより、その治療効果を向上させること
ができるが、混合した状態においては、薬剤の保有期間
（即ち、ズを命）が短くなることが多い。This fourth embodiment uses a drug release member in a system that uses multiple drugs. Although the therapeutic effect can be improved by using a mixture of two or more types of drugs, in a mixed state, the shelf life of the drugs (ie, their shelf life) is often shortened.
本第４実施例は、薬剤の放出開始時に薬剤を混合するこ
とににりこの保有期間を延長することを目的としたもの
である。The fourth embodiment aims to extend the retention period by mixing the drug at the beginning of drug release.
この第４実施例の薬剤放出部材は、上記第１実施例と同
様の材質により形成されるカブはル本体２１の内部を、
？■膜２２により分離して、分離された２つの室内に、
参照符号２３で示される薬剤Ａと、参照符号２４で示さ
れる薬剤Ｂとを収容するものである。そして、このカプ
セル本体２１には、上記第１実施例における放出孔３と
薄膜４とにそれぞれ対応する放出孔２５と簿膜２６とが
設けられている。The drug release member of this fourth embodiment has a cover body 21 formed of the same material as that of the first embodiment;
? ■Separated by membrane 22, in two separated chambers,
It accommodates medicine A indicated by reference numeral 23 and medicine B indicated by reference numeral 24. The capsule body 21 is provided with a discharge hole 25 and a membrane 26, which correspond to the discharge hole 3 and the thin membrane 4 in the first embodiment, respectively.
尚、前記カプセル本体２１の１１νでインピーダンスは
、生体及び薬剤の音響インピーダンスと近い（的のもの
とし、薄ＩＩ東２２及び２６は、音響インピーンスがカ
ブビル２１本体と比較して、より生体及び薬剤と異なる
値のしのとＪ−る。このような構成とづることにより、
薄膜が破壊しやすくなるという効果がある。The impedance of the capsule main body 21 at 11ν is close to the acoustic impedance of living organisms and drugs. Shino and J-ru of different values.By writing with such a configuration,
This has the effect of making the thin film more susceptible to destruction.
この薬剤カプセルを実際に使用づる際には、まず、カプ
セル本体２１を外＋ｉ的な処ｉｉ’７によつＣ牛体内に
埋め込み、そして、生体の外部から超音波、低周波、衝
撃波等を加える。When actually using this drug capsule, first, the capsule body 21 is implanted into the cow's body by external treatment, and then ultrasound, low frequency, shock waves, etc. are applied from outside the living body. Add.
これにより、簿膜２２が破壊されて、２種類の薬剤２３
．２４が混合されると共に、薄膜２６ ’ｂ被破壊れて
、放出孔２５から薬剤２３．２４の混合物の放出が開始
される。As a result, the membrane 22 is destroyed and the two types of drugs 23
．． 24 are mixed, the thin film 26'b is destroyed, and the release of the mixture of drugs 23 and 24 from the release hole 25 is started.
このように、本実施例によれば、薬剤の放出を開始する
際に薬剤を混合されるので、この薬剤の保有期間か延長
される。As described above, according to this embodiment, since the drug is mixed when the drug is started to be released, the retention period of the drug is extended.
［発明の効果１
以上述べたように、本発明によれば、薬剤カブしルにお
いて、薬剤放出部位を外部からの作用により破壊可能な
閉塞部材により閉塞したで、この外部から与える作用を
制郊ツることにより、生体の外部から、薬剤を放出Ｊる
時期及びその速度を制す１１ツることができる。[Effect of the Invention 1] As described above, according to the present invention, in the drug capsule, the drug release site is closed by a closing member that can be destroyed by an external action, and this external action is suppressed. By doing so, it is possible to control the timing and speed at which the drug is released from outside the body.
第１図及び第２図は本発明の第１実施例に係わり、第１
図は薬剤カブビルの構成を示１断面図、第２図は第１図
の薬剤カプセルに外部から作用が与えられたときの薄膜
の作用を示す断面図、第３図は本発明の第２実施例の薬
剤カプセルの構成を示り゛断面図、第４図は本発明の第
３実施例の薬剤カブビルの構成を示す断面図、第５図は
本発明の第３実施例の変型例の薬剤カプセルの構成を示
寸断面図、第６図は本発明の第４実施例の薬剤カプセル
の構成を示す断面図である。
１．２１・・・カプセル本体
３．２５・・・放出孔
４．１３．２２．２６・・・薄膜
１５・・・薬剤力ブセル
第１
図
第２図
第４図
（ａ）
（ｂ）
第５図
第３図
竺６図
（ａ）
（ｂ））
千彰をンｔｌｉ正けＩ（自発）
′１．事件の表示
昭和６３年持重、′１願第３０６６２４号２、発明の名
称
薬斉１／Ｊヅセル
３、ン市１１二をりる省
ＩＩ牛との関係
特１１′１出願人
住 所
名 称
東５；’ＵＩＩ渋谷区幅ヶ谷二丁目４３番２号（０３７
）オリンパス光学」−業株式会７１代表省 下 山
敏 部
４、代理人
住 所
東京都新宿区西新宿７−Ｆ［，１４番４号６、補正の対
象
明細１１：の「発明の訂細／ｊ説明」の１閲明細内第５
ペ一ジク１１６行〜第１
７行に
［−ボ
リレー乳酸」
とあるのを
［ポリ
乳酸」
（こ ？ｌＩは［
しま１゜FIG. 1 and FIG. 2 relate to the first embodiment of the present invention.
The figure is a sectional view showing the structure of the drug Kabuvir, FIG. 2 is a sectional view showing the action of the thin film when an action is applied from the outside to the drug capsule of Fig. 1, and Fig. 3 is a second embodiment of the present invention. FIG. 4 is a cross-sectional view showing the structure of the drug capsule of the third embodiment of the present invention, and FIG. 5 is a cross-sectional view showing the structure of the drug capsule of the third embodiment of the present invention. FIG. 6 is a sectional view showing the structure of a capsule according to a fourth embodiment of the present invention. 1.21...Capsule body 3.25...Release hole 4.13.22.26...Thin film 15...Pharmaceutical force cell No. 1 Figure 2 Figure 4 (a) (b) Figure 5 Figure 3 Figure 6 Figure 6 (a) (b)) Chiaki's answer I (spontaneous) '1. Description of the case 1986 Mochiju, '1 Application No. 306624 2, Name of the invention Yakuqi 1/J Zusel 3, Ng City 112, Province II Relationship with cattle Special 11'1 Applicant Address Name Name East 5;'UII 2-43-2 Hagaya, Shibuya-ku (037
) Olympus Optics” - Industry Co., Ltd. 71 Representative Ministry Satoshi Shimoyama Dept. 4, Agent address 7-F Nishi-Shinjuku, Shinjuku-ku, Tokyo [, 14 No. 4 No. 6, Specification subject to amendment 11: 5th item in 1st view of /j explanation
In lines 116 to 17 of the page, [-bolylactic acid] is replaced with [polylactic acid] (this is [shima1゜
Claims (1)
プセル本体に収納された薬剤を放出するために該カプセ
ル本体に設けた薬剤放出部位と、前記薬剤放出部位を閉
塞し外部からの作用により該薬剤放出部位を開放可能な
閉塞部材とを具備することを特徴とする薬剤カプセル。A drug capsule body for storing a drug; a drug release site provided in the capsule body for releasing the drug stored in the drug capsule body; 1. A drug capsule comprising a closure member capable of opening a release site.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63306624A JPH02152469A (en) | 1988-12-02 | 1988-12-02 | Drug capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63306624A JPH02152469A (en) | 1988-12-02 | 1988-12-02 | Drug capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02152469A true JPH02152469A (en) | 1990-06-12 |
Family
ID=17959331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63306624A Pending JPH02152469A (en) | 1988-12-02 | 1988-12-02 | Drug capsule |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02152469A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334859B1 (en) | 1999-07-26 | 2002-01-01 | Zuli Holdings Ltd. | Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments |
| JP2005177490A (en) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | Bioactive vessel occluding device which can be activated, and using method |
| JP2005177487A (en) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | Implantable bioactive medical device which can activate, and method |
| WO2010061680A1 (en) * | 2008-11-28 | 2010-06-03 | オリンパス株式会社 | Catheter |
| US7785319B2 (en) | 1999-07-26 | 2010-08-31 | Microtech Medical Technologies Ltd. | Method and apparatus for treating bodily tissues with medicinal substance |
-
1988
- 1988-12-02 JP JP63306624A patent/JPH02152469A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334859B1 (en) | 1999-07-26 | 2002-01-01 | Zuli Holdings Ltd. | Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments |
| GB2354949B (en) * | 1999-07-26 | 2003-10-22 | Zuli Holdings Ltd | Apparatus for treating body tissues with electricty |
| JP2004113807A (en) * | 1999-07-26 | 2004-04-15 | Zuli Holdings Ltd | Apparatus for treating somatic tissue by pharmaceutical |
| US7001372B2 (en) | 1999-07-26 | 2006-02-21 | Zuli Holdings, Ltd. | Apparatus and method for treating body tissues with electricity or medicaments |
| US7785319B2 (en) | 1999-07-26 | 2010-08-31 | Microtech Medical Technologies Ltd. | Method and apparatus for treating bodily tissues with medicinal substance |
| US8108041B2 (en) | 1999-07-26 | 2012-01-31 | Zuli Holdings, Ltd. | Apparatus and method for treating body tissues with electricity or medicaments |
| US9289377B2 (en) | 1999-07-26 | 2016-03-22 | Microtech Medical Technologies Ltd. | Apparatus and method for treating body tissues with electricity or medicaments |
| JP2005177490A (en) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | Bioactive vessel occluding device which can be activated, and using method |
| JP2005177487A (en) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | Implantable bioactive medical device which can activate, and method |
| JP4672356B2 (en) * | 2003-12-17 | 2011-04-20 | コーディス・ニューロバスキュラー・インコーポレイテッド | Activable and bioactive implantable medical device and method |
| WO2010061680A1 (en) * | 2008-11-28 | 2010-06-03 | オリンパス株式会社 | Catheter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240042106A1 (en) | Drug Eluting Implant | |
| KR100996990B1 (en) | Implant for implanting in bone tissue or in bone tissue supplemented with bone substitute material | |
| US5433718A (en) | Antibiotic eluding intramedullary nail apparatus | |
| US5653760A (en) | Method and apparatus for managing macromolecular distribution | |
| Tayapongsak et al. | Autologous fibrin adhesive in mandibular reconstruction with particulate cancellous bone and marrow | |
| CN102458272B (en) | Devices and methods for treating pain associated with tonsillectomies | |
| US9089450B2 (en) | Implantatable component having an accessible lumen and a drug release capsule for introduction into same | |
| US5429634A (en) | Biogenic implant for drug delivery and method | |
| US9005184B2 (en) | Device to be implanted in a human or animal body for material or signal delivery or acquisition within the body, and method of implanting the device | |
| DE60111068D1 (en) | POLYMIC ADMINISTRATION OF LEUPROLIDE WITH IMPROVED EFFICACY | |
| AU2021203915B2 (en) | Two-part implantable therapy delivery device | |
| JP2019508213A (en) | Method for producing biocompatible porcine cartilage-derived extracellular matrix membrane capable of controlling biodegradation rate and physical properties, and composition for preventing adhesion comprising the porcine cartilage-derived extracellular matrix as an active ingredient | |
| ES2613943T3 (en) | Implants for drug administration | |
| Yang et al. | Stimulation of fracture healing in a canine ulna full-defect model by low-intensity pulsed ultrasound | |
| JPH02152469A (en) | Drug capsule | |
| US20040037866A1 (en) | Composition and method for the treatment and prevention of adhesions | |
| JPH01212559A (en) | Biological implant substance | |
| Feldman et al. | Compatibility of autologous fibrin adhesive with implant materials | |
| CN101304708B (en) | Sclerotic ring cingulum and manufacturing method thereof | |
| HUP0203908A2 (en) | Osmotic delivery system and method for delivery first of all of medicine | |
| KAPLAN | A Technique of Nonsuture Wound Closure with a Plastic Tissue Adhesiveb | |
| EP3621552B1 (en) | A device for carrying out a method for the non-invasive fragmentation of residual biomaterial after bone augmentation | |
| RU2155049C1 (en) | Osteoplasty composition | |
| TWI245652B (en) | Structure of bio-absorbable type drug release agent and its manufacturing method | |
| WO2007136663A3 (en) | Antibiotic/bone morphogenic protein formulation and method of treatment |